Targeting this VEGFR-2/PI3 K/AKT axis is thus regarded as a strategic approach to inhibiting synovial angiogenesis in RA, and CPD-002 is currently being studied as a potential inhibitor of this pathway (Jiang et al. 2024). The gene discussed is KDR; the disease is rheumatoid arthritis.